• PROS (PIK3CA‑Related Overgrowth Spectrum) and, research hub

An open label, multi-center alpelisib roll-over study to assess long-term safety in participants who have completed a Novartis sponsored alpelisib (BYL719) study and are judged by the Investigator to benefit from continued treatment with alpelisib.

This study is an extension study for adults who have already taken the medicine alpelisib in a previous clinical trial for breast cancer or a rare overgrowth condition called PROS. It allows patients to continue their treatment while doctors monitor its long-term safety and how well it keeps working.